VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA

Their core work

Turku University Central Hospital (TUCH) is a major Finnish hospital district serving Southwest Finland, combining clinical care with clinical research. In H2020, they contribute real-world patient data, clinical trial infrastructure, and medical imaging expertise to European health research consortia. Their involvement spans respiratory disease surveillance, cancer treatment, diabetes biomarker research, and sleep medicine — always from the perspective of a large hospital generating and analyzing patient-level clinical data.

What they specialise in

How they've shifted over time

In 2016–2019, TUCH focused on disease-specific clinical research — diabetic kidney disease biomarkers (BEAt-DKD), RSV epidemiology (RESCEU), coronary artery simulation (SMARTool), and ovarian cancer characterization (HERCULES). From 2019 onward, the emphasis shifted decisively toward AI and digital health applications: artificial intelligence for cancer treatment decisions (DECIDER), machine learning for sleep diagnostics (SLEEP REVOLUTION), and continued RSV surveillance with modern data methods (PROMISE). The hospital is clearly transitioning from being a traditional clinical data provider to an active participant in AI-powered personalized medicine.

TUCH is moving from contributing patient cohorts to traditional clinical studies toward integrating AI and digital tools into clinical workflows — expect future projects at the intersection of hospital data and machine learning.

How they like to work

TUCH has never coordinated an H2020 project, consistently joining as a participant (6 projects) or third party (2 projects), which is typical for a hospital contributing clinical data and patient access rather than leading research design. With 129 unique partners across 26 countries, they operate in large, multi-center consortia — the kind needed for statistically powered clinical studies. This makes them a reliable clinical site partner who can deliver patient data and domain expertise without requiring project leadership overhead.

TUCH has collaborated with 129 unique partners across 26 countries, reflecting the large multi-center clinical consortia typical in health research. Their network spans broadly across Europe with no single dominant geographic cluster.

What sets them apart

As a major Finnish hospital district, TUCH offers what academic labs cannot: direct access to real-world patient populations, clinical infrastructure, and longitudinal health records within the Finnish healthcare system. Finland's population registries and electronic health records are among the most comprehensive in Europe, making TUCH particularly valuable for projects requiring high-quality retrospective and prospective clinical data. Their growing AI capabilities, combined with this data asset, position them well for digital health and personalized medicine consortia.

Highlights from their portfolio

• RESCEU
  Largest funded project (EUR 595,750) — a major European RSV consortium that built foundational surveillance data now informing RSV vaccine policy.
• DECIDER
  Represents TUCH's strategic shift into AI, applying artificial intelligence to overcome chemotherapy resistance in cancer treatment.
• BEAt-DKD
  Large IMI joint undertaking tackling diabetic kidney disease with multi-omics biomarkers — shows TUCH's capacity for complex biomarker-driven research.